{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 461936569
| IUPAC_name = (2S)-2-<nowiki>[[</nowiki>(3aS,7aS)-1-[2-[(2S)-2-<nowiki>[[</nowiki>(2S)-<BR/>2-<nowiki>[[</nowiki>2-<nowiki>[[</nowiki>(4R)-1-[1-[2-<nowiki>[[</nowiki>(2R)-2-amino-5-(diaminomethylideneamino)<BR/>pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-<BR/>2-carbonyl]-4-hydroxypyrrolidine-2-carbonyl]amino]acetyl]amino]-<BR/>3-thiophen-2-ylpropanoyl]amino]-3-hydroxypropanoyl]<BR/>3,4-dihydro-1H-isoquinoline-3-carbonyl]<BR/>2,3,3a,4,5,6,7,7a-octahydroindole-2-carbonyl]amino]-<BR/>5-(diaminomethylideneamino)pentanoic acid
| image = Icatibant.svg

<!--Clinical data-->
| tradename = Firazyr
| synonyms  = Hoe 140, JE 049<ref>{{Cite journal|title = Icatibant: HOE 140, JE 049, JE049. | pmid=15563238 | volume=5 | journal=Drugs R D | pages=343-8}}</ref>
| Drugs.com = {{drugs.com|international|icatibant}}
| licence_EU = Firazyr
| licence_US = Icatibant
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = C
| pregnancy_category =  
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
| legal_US = Rx-only
| legal_status =  
| routes_of_administration = subcutaneous

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  

<!--Identifiers-->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 130308-48-4
| ATC_prefix = B06
| ATC_suffix = AC02
| ATC_supplemental =  
| PubChem = 71364
| IUPHAR_ligand = 667
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB06196
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 16736634
| ChEBI_Ref = {{ebicite|changed|EBI}}
| ChEBI = 68556
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 7PG89G35Q7
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1743581

<!--Chemical data-->
| C=59 | H=89 | N=19 | O=13 | S=1 
| molecular_weight = 1304.52 g/mol
| smiles = C1CC[C@H]2[C@@H](C1)CC(N2C(=O)C3CC4=CC=CC=C4CN3C(=O)[C@H](CO)NC(=O)[C@H](CC5=CC=CS5)NC(=O)CNC(=O)C6C[C@H](CN6C(=O)C7CCCN7C(=O)C(CCCN=C(N)N)NC(=O)[C@@H](CCCN=C(N)N)N)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C59H89N19O13S/c60-37(14-5-19-67-57(61)62)48(82)72-38(15-6-20-68-58(63)64)52(86)75-22-8-18-43(75)54(88)77-30-35(80)26-44(77)50(84)70-28-47(81)71-40(27-36-13-9-23-92-36)49(83)74-41(31-79)53(87)76-29-34-12-2-1-10-32(34)24-46(76)55(89)78-42-17-4-3-11-33(42)25-45(78)51(85)73-39(56(90)91)16-7-21-69-59(65)66/h1-2,9-10,12-13,23,33,35,37-46,79-80H,3-8,11,14-22,24-31,60H2,(H,70,84)(H,71,81)(H,72,82)(H,73,85)(H,74,83)(H,90,91)(H4,61,62,67)(H4,63,64,68)(H4,65,66,69)/t33-,35+,37+,38-,39-,40-,41-,42-,43-,44-,45?,46+/m0/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = QURWXBZNHXJZBE-OVZQYVDUSA-N
}}

'''Icatibant''', trade name '''Firazyr''', is medication that has been approved by the [[European Commission]] for the symptomatic treatment of acute attacks of [[hereditary angioedema]] (HAE) in adults with [[C1 inhibitor|C1-esterase-inhibitor]] deficiency.<ref name=Jerini2008>{{cite press release|title=Jerini Receives European Commission Approval for Firazyr (Icatibant) in the Treatment of HAE |publisher=[[Jerini|Jerini AG]] |date=2008-07-15 |url=http://www.jerini.com/cms/en/05-news-events/05-01-corporate-news/05-01-07-newsarchive-2008/08-07-15_EU_Approval.php?back=true |accessdate=2008-07-22 }}{{dead link|date=April 2017 |bot=InternetArchiveBot |fix-attempted=yes }}</ref> It is not effective in angioedema caused by medication from the [[ACE inhibitor]] class, as shown in a 2017 trial.<ref>{{cite journal|last1=Sinert|first1=R|last2=Levy|first2=P|last3=Bernstein|first3=JA|last4=Body|first4=R|last5=Sivilotti|first5=MLA|last6=Moellman|first6=J|last7=Schranz|first7=J|last8=Baptista|first8=J|last9=Kimura|first9=A|last10=Nothaft|first10=W|last11=CAMEO study|first11=group.|title=Randomized Trial of Icatibant for Angiotensin-Converting Enzyme Inhibitor-Induced Upper Airway Angioedema.|journal=The journal of allergy and clinical immunology. In practice|date=undefined NaN|volume=5|issue=5|pages=1402-1409.e3|doi=10.1016/j.jaip.2017.03.003|pmid=28552382}}</ref>

It is a [[peptidomimetic]] consisting of ten [[amino acid]]s, which is a selective and specific antagonist of [[bradykinin]] [[Bradykinin receptor B2|B2 receptors]]. 

==Mechanism of action==
Bradykinin is a peptide-based hormone that is formed locally in tissues, very often in response to a trauma. It increases vessel permeability, [[Vasodilation|dilates blood vessels]] and causes [[smooth muscle cell]]s to contract. Bradykinin plays an important role as the mediator of pain. Surplus [[bradykinin]] is responsible for the typical symptoms of inflammation, such as swelling, [[Erythema|redness]], overheating and pain. These symptoms are mediated by activation of bradykinin B2 receptors. Icatibant acts as a bradykinin inhibitor by blocking the binding of native bradykinin to the bradykinin B2 receptor.

==Regulatory status==
Icatibant has received [[orphan drug]] status in Australia, EU, Switzerland and US for the treatment of hereditary angioedema (HAE). 

In the EU, the approval by the European Commission (July 2008) allows [[Jerini AG|Jerini]] to market Firazyr in the European Union's 27 member states, as well as Switzerland, Lichtenstein and Iceland, making it the first product to be approved in all EU countries for the treatment of HAE.<ref name="Jerini2008"/> In the US, the drug was granted FDA approval on August 25, 2011.<ref>{{cite press release|url=http://www.shire.com/shireplc/en/media/shirenews?id=520 |title=FDA Approves Shireâ€™s FIRAZYR (icatibant injection) for Acute Attacks of Hereditary Angioedema (HAE) |publisher=Shire |accessdate=2011-08-28}}</ref>

==See also==
* [[Ecallantide]], another drug for the treatment of HAE

==References==
{{Reflist}}

{{B03, B05, B06}}
{{Peptidergics}}

[[Category:Anti-inflammatory agents]]
[[Category:Peptides]]
[[Category:Orphan drugs]]